Core Viewpoint - Herbal Dispatch Inc. is conducting a non-brokered private placement aiming to raise up to $1,000,000, with strong interest potentially leading to an oversubscription of up to $2,000,000 [1][2]. Group 1: Private Placement Details - The company plans to issue up to 20,000,000 units at a price of $0.05 per unit, with gross proceeds expected to reach $1,000,000 [1]. - Due to high demand, the private placement may be oversubscribed, allowing for the issuance of up to 40,000,000 units for gross proceeds of up to $2,000,000, which has been approved by the Canadian Securities Exchange [2]. - The closing of the private placement is anticipated to occur around September 19, 2025 [2]. Group 2: Use of Proceeds - Proceeds from the private placement and any oversubscription will be allocated for working capital, including inventory purchases to support export sales growth, supplier payments, and upcoming principal loan payments [3]. Group 3: Company Overview - Herbal Dispatch Inc. operates leading cannabis e-commerce platforms, focusing on providing high-quality cannabis products at affordable prices [4]. - The company's flagship marketplace, herbaldispatch.com, offers exclusive access to small-batch craft cannabis and a variety of product formats [4].

Industry Trend - Cannabis companies are increasingly using an arcane legal tool [1] - Competition in the weed industry is forcing former startups to restructure their debts [1]

Core Insights - High Tide's Canna Cabana retail cannabis store has shown consistent growth, reaching 203 locations across Canada by July 2025, with significant expansions in Alberta and Ontario [1][8] - Canna Cabana achieved a 12% market share in the cannabis retail market, with stores generating 2.3 times the revenue of competitors [2][8] - The Canadian legal cannabis market was valued at $3.25 billion in 2024, with a projected CAGR of 12% from 2025 to 2030, driven by federal legalization and increased health awareness [3] Company Performance - High Tide's shares increased by 76.2% over the past year, significantly outperforming the industry growth of 3.3% and the S&P 500's 15.5% [7] - The company reported approximately $6.8 million in retail sales from April 17 to April 20, 2025 [2] Market Dynamics - The Ontario government increased the cannabis retail store cap from 75 to 150 locations, enhancing High Tide's growth potential in the largest cannabis market in Canada [3][8] - Peer companies like Village Farms and Aurora Cannabis are also experiencing significant growth, with Village Farms reporting a 690% increase in international medical export sales and Aurora Cannabis seeing an 85% rise in international medical cannabis sales [4][6] Valuation Metrics - High Tide currently trades at a forward Price-to-Sales (P/S) ratio of 0.55X, compared to the industry average of 5.60X, indicating a discounted valuation [9]

Group 1 - The cannabis industry is experiencing increased speculation regarding the potential reclassification of cannabis from a Schedule 1 to a Schedule 3 substance, which could have significant implications for the market [1] - Comments regarding the reclassification gained credibility following statements made by President on August 11th, indicating a shift in regulatory perspective [1] Group 2 - The author of the article has extensive experience in finance and investment banking, including founding a nationwide investment banking firm and writing multiple publications on cannabis stocks [1]

Core Insights - Momentum investors focus on "buying high and selling higher" rather than traditional strategies of buying low and waiting for recovery [1] - Identifying the right entry point for fast-moving stocks can be challenging, as they may lose momentum if future growth does not justify their high valuations [2] Group 1: Investment Strategy - A safer investment approach involves targeting bargain stocks that exhibit recent price momentum [3] - The Zacks Momentum Style Score aids in identifying strong momentum stocks by analyzing price and earnings trends [3] Group 2: MariMed Inc. (MRMD) Analysis - MariMed Inc. (MRMD) has shown significant price momentum, with a four-week price change of 58% and a 12-week gain of 114.2% [4][5] - MRMD has a high beta of 3, indicating it moves 200% more than the market in either direction, suggesting strong volatility [5] - The stock has a Momentum Score of B, indicating a favorable time to invest [6] Group 3: Earnings and Valuation - MRMD has received a Zacks Rank 2 (Buy) due to upward revisions in earnings estimates, which attract more investor interest [7] - The stock is currently trading at a Price-to-Sales ratio of 0.38, indicating it is undervalued at 38 cents for each dollar of sales [7] Group 4: Additional Opportunities - Besides MRMD, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, suggesting further investment opportunities [8] - Zacks offers over 45 Premium Screens tailored to different investing styles, which can help identify potential winning stocks [9]

Group 1 - Cannara Biotech Inc. has approved the grant of incentive awards under its stock option plan and restricted share unit compensation plan [1][2] - The awards were granted in alignment with the completion of the Company's fiscal year-end on August 31, 2025, marking five consecutive years of commercial operations and year-over-year revenue growth [2] - The Company has granted 3,625,000 stock options to certain employees, each exercisable into one common share at an exercise price of $1.44 per share, vesting over three years [5] Group 2 - Cannara operates two mega facilities in Québec, covering over 1,650,000 sq. ft., with a potential annualized cultivation output of 100,000 kg [4] - The Company leverages Québec's low electricity costs to produce premium-grade cannabis products at affordable prices [4] - 145,000 restricted share units (RSUs) were granted to members of the board of directors, vesting in full on the second anniversary of the grant date [5]

Why Cheech And Chong’s $100 Million Cannabis Empire Is No Joke https://t.co/1CKikEKnPj https://t.co/6Tfpp9jZZR ...

Why Cheech And Chong’s $100 Million Cannabis Empire Is No Joke https://t.co/6rpMTeiRZL https://t.co/klMy9TkOqE ...

Group 1 - The cannabis industry, including multi-state operator Cresco Labs, is facing significant challenges such as black- and gray-market competition, limited access to financial services, and high taxation [1][2] - Cresco Labs' stock performance has been poor, with a $1,000 investment in the stock shrinking to approximately $200 over the past five years, while the S&P 500 index would have grown to $1,878 in the same period [2] - The legal status of cannabis in the U.S. is complicated, with federal illegality contrasted by varying state laws, leading to a patchwork of legalization across the country [4] Group 2 - There is ongoing lobbying for federal rescheduling of marijuana, but it is not a priority for lawmakers, leaving companies like Cresco in a survival mode [5] - Cresco Labs is experiencing declining revenue and ongoing challenges with profitability, although it has recently refinanced a $325 million credit facility and holds $147 million in cash and equivalents [6]

Why Cheech And Chong’s $100 Million Cannabis Empire Is No Joke https://t.co/VTfsB854rd https://t.co/nJ8CQ14TOb ...